KEYTRUDA QLEX 2000 U/mL
pembrolizumab and berahyaluronidase alfa-pmph · INJECTION, SOLUTION · Merck Sharp & Dohme LLC
KEYTRUDA QLEX is a injection, solution containing pembrolizumab and berahyaluronidase alfa-pmph at 2000 U/mL, taken subcutaneous. Manufactured by Merck Sharp & Dohme LLC.
Key Facts
- Brand Name
- KEYTRUDA QLEX
- Generic Name
- pembrolizumab and berahyaluronidase alfa-pmph
- NDC Code (Product)
0006-3083- Manufacturer
- Merck Sharp & Dohme LLC
- Strength
- 2000 U/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761467
- Drug Class
- Programmed Death Receptor-1 Blocking Antibody [EPC]; Endoglycosidase [EPC]
- Marketing Start
- 09/19/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is KEYTRUDA QLEX used for?
KEYTRUDA QLEX contains pembrolizumab and berahyaluronidase alfa-pmph. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is KEYTRUDA QLEX a controlled substance?
KEYTRUDA QLEX is not classified as a controlled substance by the DEA.
What is the generic name for KEYTRUDA QLEX?
The generic name for KEYTRUDA QLEX is pembrolizumab and berahyaluronidase alfa-pmph. There are no other listed brand versions of pembrolizumab and berahyaluronidase alfa-pmph.
What is the NDC code for KEYTRUDA QLEX 2000 U/mL?
The NDC (National Drug Code) for KEYTRUDA QLEX 2000 U/mL is 0006-3083, listed by Merck Sharp & Dohme LLC.
Other KEYTRUDA QLEX Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)